213 related articles for article (PubMed ID: 21240255)
1. Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma.
Shih IeM; Nakayama K; Wu G; Nakayama N; Zhang J; Wang TL
Mod Pathol; 2011 May; 24(5):638-45. PubMed ID: 21240255
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas.
Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama N; Otsuki Y; Nakayama S; Miyazaki K
Br J Cancer; 2012 Jul; 107(2):300-7. PubMed ID: 22653145
[TBL] [Abstract][Full Text] [Related]
3. Amplicon profiles in ovarian serous carcinomas.
Nakayama K; Nakayama N; Jinawath N; Salani R; Kurman RJ; Shih IeM; Wang TL
Int J Cancer; 2007 Jun; 120(12):2613-7. PubMed ID: 17351921
[TBL] [Abstract][Full Text] [Related]
4. Amplification of 11q13 in ovarian carcinoma.
Brown LA; Kalloger SE; Miller MA; Shih IeM; McKinney SE; Santos JL; Swenerton K; Spellman PT; Gray J; Gilks CB; Huntsman DG
Genes Chromosomes Cancer; 2008 Jun; 47(6):481-9. PubMed ID: 18314909
[TBL] [Abstract][Full Text] [Related]
5. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.
Lassus H; Leminen A; Vayrynen A; Cheng G; Gustafsson JA; Isola J; Butzow R
Gynecol Oncol; 2004 Jan; 92(1):31-9. PubMed ID: 14751135
[TBL] [Abstract][Full Text] [Related]
6. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary.
Schmandt RE; Bennett M; Clifford S; Thornton A; Jiang F; Broaddus RR; Sun CC; Lu KH; Sood AK; Gershenson DM
Cancer Biol Ther; 2006 Sep; 5(9):1136-41. PubMed ID: 16855388
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
[TBL] [Abstract][Full Text] [Related]
8. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.
Brown LA; Irving J; Parker R; Kim H; Press JZ; Longacre TA; Chia S; Magliocco A; Makretsov N; Gilks B; Pollack J; Huntsman D
Gynecol Oncol; 2006 Feb; 100(2):264-70. PubMed ID: 16236351
[TBL] [Abstract][Full Text] [Related]
9. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer.
King ER; Tung CS; Tsang YT; Zu Z; Lok GT; Deavers MT; Malpica A; Wolf JK; Lu KH; Birrer MJ; Mok SC; Gershenson DM; Wong KK
Am J Surg Pathol; 2011 Jun; 35(6):904-12. PubMed ID: 21451362
[TBL] [Abstract][Full Text] [Related]
10. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.
Sung CO; Song IH; Sohn I
Gynecol Oncol; 2014 Feb; 132(2):343-50. PubMed ID: 24321399
[TBL] [Abstract][Full Text] [Related]
11. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma.
Yang S; Zhang Y; Meng F; Liu Y; Xia B; Xiao M; Xu Y; Ning X; Li H; Lou G
Biomarkers; 2013 May; 18(3):257-63. PubMed ID: 23566000
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.
Clauss A; Ng V; Liu J; Piao H; Russo M; Vena N; Sheng Q; Hirsch MS; Bonome T; Matulonis U; Ligon AH; Birrer MJ; Drapkin R
Neoplasia; 2010 Feb; 12(2):161-72. PubMed ID: 20126474
[TBL] [Abstract][Full Text] [Related]
14. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.
Tung CS; Mok SC; Tsang YT; Zu Z; Song H; Liu J; Deavers MT; Malpica A; Wolf JK; Lu KH; Gershenson DM; Wong KK
Mod Pathol; 2009 Sep; 22(9):1243-50. PubMed ID: 19525924
[TBL] [Abstract][Full Text] [Related]
15. Biological role and prognostic significance of NAC1 in ovarian cancer.
Nakayama K; Rahman MT; Rahman M; Yeasmin S; Ishikawa M; Katagiri A; Iida K; Nakayama N; Miyazaki K
Gynecol Oncol; 2010 Dec; 119(3):469-78. PubMed ID: 20869761
[TBL] [Abstract][Full Text] [Related]
16. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays.
Mayr D; Kanitz V; Anderegg B; Luthardt B; Engel J; Löhrs U; Amann G; Diebold J
Am J Clin Pathol; 2006 Jul; 126(1):101-9. PubMed ID: 16753589
[TBL] [Abstract][Full Text] [Related]
17. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; ; Bowtell D; Waring P
Gynecol Oncol; 2018 Nov; 151(2):327-336. PubMed ID: 30209015
[TBL] [Abstract][Full Text] [Related]
18. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.
Kuo KT; Guan B; Feng Y; Mao TL; Chen X; Jinawath N; Wang Y; Kurman RJ; Shih IeM; Wang TL
Cancer Res; 2009 May; 69(9):4036-42. PubMed ID: 19383911
[TBL] [Abstract][Full Text] [Related]
19. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
20. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study.
Dugo M; Devecchi A; De Cecco L; Cecchin E; Mezzanzanica D; Sensi M; Bagnoli M
Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31491988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
